Search
Tirzepatide Treatment Options in Illinois
A collection of 29 research studies where Tirzepatide is the interventional treatment. These studies are located in the Illinois, United States. Tirzepatide is used for conditions such as Obesity, Overweight and Type 2 Diabetes.
25 - 29 of 29
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Stroke Clinical Study
Recruiting
A clinical study for people that suffer with Stroke
Conditions:
Stroke
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss
Completed
This was a study of tirzepatide in participants with obesity or overweight. The main purpose was to learn more about how tirzepatide maintained body weight loss. The study had two phases: a lead-in phase in which all participants took tirzepatide and a treatment phase in which participants either continued tirzepatide or switched to placebo. The study lasted about 2 years (25 visits).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2024
Locations: Healthcare Research Network - Chicago, Flossmoor, Illinois +1 locations
Conditions: Obesity, Overweight
A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program
Completed
This is a study of tirzepatide in participants with obesity. The purpose of this study is to learn more about how tirzepatide maintains body weight or adds to weight loss after an intensive lifestyle modification program. The study will last about 2 years (29 visits).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2024
Locations: Evanston Premier Healthcare Research LLC, Evanston, Illinois
Conditions: Obesity, Overweight
A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin
Completed
The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide to insulin lispro (U100) three times a day in participants with type 2 diabetes that are already on insulin glargine (U100), with or without metformin.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/10/2023
Locations: J H. Stroger Hosp of Cook Co, Chicago, Illinois +1 locations
Conditions: Type 2 Diabetes
A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk
Completed
The purpose of the trial is to assess the efficacy and safety of tirzepatide taken once a week to insulin glargine taken once daily in participants with type 2 diabetes and increased cardiovascular risk. The study will last about 108 weeks and may include up to 30 visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/21/2022
Locations: Northwestern Feinberg School of Medicine, Chicago, Illinois +1 locations
Conditions: Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes
Completed
The purpose of this study is to compare the effect of the study drug tirzepatide to insulin degludec on blood sugar levels in participants with type 2 diabetes. The study will last about 67 weeks and may include up to 22 visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/14/2022
Locations: Springfield Diabetes & Endocrine Center, Springfield, Illinois
Conditions: Type 2 Diabetes Mellitus
25 - 29 of 29